ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,769.00
0.41%
S&P ASX All Technology
3,068.30
0.93%
Brent Oil
77.66
0.71%
US Dollar vs AUD
1.50534
0.04%
Bitcoin
70,840.30
0.31%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) News

CSTL

Castle Biosciences (CSTL)

Castle Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CSTL
DateTimeSourceHeadlineSymbolCompany
05/06/202408:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
31/05/202406:30Business WireCastle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging SurveillanceNASDAQ:CSTLCastle Biosciences Inc
30/05/202406:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
30/05/202406:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
30/05/202406:30Business WireNew Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of MetastasisNASDAQ:CSTLCastle Biosciences Inc
29/05/202406:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
29/05/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
29/05/202406:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
29/05/202406:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
25/05/202406:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CSTLCastle Biosciences Inc
15/05/202421:00Business WireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceNASDAQ:CSTLCastle Biosciences Inc
14/05/202421:00Business WireCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024NASDAQ:CSTLCastle Biosciences Inc
11/05/202405:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
10/05/202421:00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
09/05/202406:30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
03/05/202421:00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
03/05/202406:05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
01/05/202406:30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
11/04/202421:00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
11/04/202407:00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
10/04/202421:00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
05/04/202407:30Business WirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerNASDAQ:CSTLCastle Biosciences Inc
02/04/202422:00Business WireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CSTLCastle Biosciences Inc
28/03/202408:00Business WireCastle Biosciences Announces Updates to its Board of DirectorsNASDAQ:CSTLCastle Biosciences Inc
25/03/202422:00Business WireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
23/03/202407:30Business WireLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBNASDAQ:CSTLCastle Biosciences Inc
19/03/202422:00Business WireLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyNASDAQ:CSTLCastle Biosciences Inc
16/03/202407:30Business WireNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderNASDAQ:CSTLCastle Biosciences Inc
12/03/202422:00Business WireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumNASDAQ:CSTLCastle Biosciences Inc
09/03/202408:30Business WireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CSTLCastle Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CSTL

Your Recent History

TIDE
CAKEBTC
PancakeSwap Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved